PROTAC Chemical Probes for Histone Deacetylase Enzymes

Overview

Journal RSC Chem Biol

Publisher Royal Society of Chemistry

Specialty Biology

Date 2023 Sep 1

PMID 37654508

Authors

Urvashi Patel

Joshua P Smalley

James T Hodgkinson

Affiliations

Soon will be listed here.

Abstract

Over the past three decades, we have witnessed the progression of small molecule chemical probes designed to inhibit the catalytic active site of histone deacetylase (HDAC) enzymes into FDA approved drugs. However, it is only in the past five years we have witnessed the emergence of proteolysis targeting chimeras (PROTACs) capable of promoting the proteasome mediated degradation of HDACs. This is a field still in its infancy, however given the current progress of PROTACs in clinical trials and the fact that FDA approved HDAC drugs are already in the clinic, there is significant potential in developing PROTACs to target HDACs as therapeutics. Beyond therapeutics, PROTACs also serve important applications as chemical probes to interrogate fundamental biology related to HDACs their unique degradation mode of action. In this review, we highlight some of the key findings to date in the discovery of PROTACs targeting HDACs by HDAC class and HDAC isoenzyme, current gaps in PROTACs to target HDACs and future outlooks.

Citing Articles

Epigenetic drugs in cancer therapy.

Suraweera A, OByrne K, Richard D Cancer Metastasis Rev. 2025; 44(1):37.

PMID: 40011240 PMC: 11865116. DOI: 10.1007/s10555-025-10253-7.

Development of the First-in-Class FEM1B-Recruiting Histone Deacetylase Degraders.

Feller F, Honin I, Miranda M, Weber H, Henze S, Hanl M J Med Chem. 2025; 68(2):1824-1843.

PMID: 39804678 PMC: 11780399. DOI: 10.1021/acs.jmedchem.4c02569.

Correction: Curcio et al. The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods. 2024, , 620.

Curcio A, Rocca R, Alcaro S, Artese A Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598470 PMC: 11597655. DOI: 10.3390/ph17111520.

Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions.

Kamaraj R, Ghosh S, Das S, Sen S, Kumar P, Majumdar M Bioconjug Chem. 2024; 35(8):1089-1115.

PMID: 38990186 PMC: 11342303. DOI: 10.1021/acs.bioconjchem.4c00253.

The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods.

Curcio A, Rocca R, Alcaro S, Artese A Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794190 PMC: 11124352. DOI: 10.3390/ph17050620.

References

Millard C, Watson P, Fairall L, Schwabe J . Targeting Class I Histone Deacetylases in a "Complex" Environment. Trends Pharmacol Sci. 2017; 38(4):363-377. DOI: 10.1016/j.tips.2016.12.006. View

Gao L, Cueto M, Asselbergs F, Atadja P . Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem. 2002; 277(28):25748-55. DOI: 10.1074/jbc.M111871200. View

Li X, Song S, Liu Y, Ko S, Kao H . Phosphorylation of the histone deacetylase 7 modulates its stability and association with 14-3-3 proteins. J Biol Chem. 2004; 279(33):34201-8. DOI: 10.1074/jbc.M405179200. View

Guha M . HDAC inhibitors still need a home run, despite recent approval. Nat Rev Drug Discov. 2015; 14(4):225-6. DOI: 10.1038/nrd4583. View

Burslem G, Crews C . Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery. Cell. 2020; 181(1):102-114. PMC: 7319047. DOI: 10.1016/j.cell.2019.11.031. View

Darwish S, Ghazy E, Heimburg T, Herp D, Zeyen P, Salem-Altintas R . Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity. Int J Mol Sci. 2022; 23(14). PMC: 9322761. DOI: 10.3390/ijms23147535. View

Yang K, Zhao Y, Nie X, Wu H, Wang B, Almodovar-Rivera C . A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders. Cell Chem Biol. 2020; 27(7):866-876.e8. PMC: 7368820. DOI: 10.1016/j.chembiol.2020.04.008. View

Gupta M, Han J, Stenson M, Wellik L, Witzig T . Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy. Leukemia. 2011; 26(6):1356-64. PMC: 3625618. DOI: 10.1038/leu.2011.340. View

Lahm A, Paolini C, Pallaoro M, Nardi M, Jones P, Neddermann P . Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci U S A. 2007; 104(44):17335-40. PMC: 2077257. DOI: 10.1073/pnas.0706487104. View

10.

Borcoman E, Kamal M, Marret G, Dupain C, Castel-Ajgal Z, Le Tourneau C . HDAC Inhibition to Prime Immune Checkpoint Inhibitors. Cancers (Basel). 2022; 14(1). PMC: 8750966. DOI: 10.3390/cancers14010066. View

11.

Bieliauskas A, Pflum M . Isoform-selective histone deacetylase inhibitors. Chem Soc Rev. 2008; 37(7):1402-13. PMC: 2593472. DOI: 10.1039/b703830p. View

12.

Sun L, Marin de Evsikova C, Bian K, Achille A, Telles E, Pei H . Programming and Regulation of Metabolic Homeostasis by HDAC11. EBioMedicine. 2018; 33:157-168. PMC: 6085537. DOI: 10.1016/j.ebiom.2018.06.025. View

13.

Iegre J, Atkinson E, Brear P, Cooper B, Hyvonen M, Spring D . Chemical probes targeting the kinase CK2: a journey outside the catalytic box. Org Biomol Chem. 2021; 19(20):4380-4396. DOI: 10.1039/d1ob00257k. View

14.

Huang J, Zhang J, Xu W, Wu Q, Zeng R, Liu Z . Structure-Based Discovery of Selective Histone Deacetylase 8 Degraders with Potent Anticancer Activity. J Med Chem. 2022; 66(2):1186-1209. DOI: 10.1021/acs.jmedchem.2c00739. View

15.

Grunstein M . Histone acetylation in chromatin structure and transcription. Nature. 1997; 389(6649):349-52. DOI: 10.1038/38664. View

16.

Bekes M, Langley D, Crews C . PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022; 21(3):181-200. PMC: 8765495. DOI: 10.1038/s41573-021-00371-6. View

17.

Nemec V, Schwalm M, Muller S, Knapp S . PROTAC degraders as chemical probes for studying target biology and target validation. Chem Soc Rev. 2022; 51(18):7971-7993. DOI: 10.1039/d2cs00478j. View

18.

Seto E, Yoshida M . Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol. 2014; 6(4):a018713. PMC: 3970420. DOI: 10.1101/cshperspect.a018713. View

19.

Geraldy M, Morgen M, Sehr P, Steimbach R, Moi D, Ridinger J . Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated. J Med Chem. 2019; 62(9):4426-4443. DOI: 10.1021/acs.jmedchem.8b01936. View

20.

Kim J, Cho H, Yoo J, Kim G, Jeon Y, Lee S . Pathological Role of HDAC8: Cancer and Beyond. Cells. 2022; 11(19). PMC: 9563588. DOI: 10.3390/cells11193161. View